特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
661176

プレフィルドシリンジの世界市場:材料、アプリケーション、タイプ、地域別の成長率、動向および予測(2018年~2023年)

Prefilled Syringes Market Size - Growth, Trends, and Forecast (2020-2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 114 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
プレフィルドシリンジの世界市場:材料、アプリケーション、タイプ、地域別の成長率、動向および予測(2018年~2023年)
出版日: 2020年08月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 114 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のプレフィルドシリンジ市場は、2018年から2023年の予測期間中に、10.5%の成長率を記録すると予測されています。プレフィルドシリンジは、従来の方法と比較して、注射による薬物送達を行うためのより簡単な方法を提供します。これに加えて、医療従事者の時間と労力を節約できます。また、活性医薬成分(API)の浪費を低減します。患者の安全性の向上と病院のミスを減らすための医療従事者の努力により、プレフィルドシリンジの需要が高まっています。欧州市場は、セルフケア機器の導入の増加と主要企業の存在により、市場シェアが最大になると見込まれています。

当レポートでは、世界のプレフィルドシリンジ市場を調査し、全体的な市場動向、材料・アプリケーション・タイプ・地域別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • パイプライン分析
  • ポーターのファイブフォース分析
    • サプライヤーの交渉力
    • 消費者の交渉力
    • 新規参入の脅威
    • 代替製品とサービスの脅威
    • 業界内での競争
  • 規制のシナリオ

第6章 成長要因、阻害要因、機会と挑戦分析(DROC)

  • 市場の成長要因
    • セルフケア機器の普及
    • プレフィルドシリンジに関するメリット
    • 生物製剤向けプレフィルドシリンジの使用増加
  • 市場の阻害要因
    • 製品リコール
    • 代替薬物送達方法の利用可能性
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 材料別
    • ガラス製プリフィルドシリンジ
    • プラスチック製プレフィルドシリンジ
  • アプリケーション別
    • 糖尿病
    • アナフィラキシー
    • 関節炎
    • ワクチン
    • その他
  • タイプ別
    • 使い捨てプレフィルドシリンジ
    • 再使用可能なプレフィルドシリンジ
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Becton, Dickinson and Company
  • Gerresheimer AG
  • Haselmeier AG
  • Medtronic
  • ニプロ
  • Scandinavian Health Limited (SHL Group)
  • SCHOTT
  • Stevanato Group
  • テルモ
  • Unilife Corporation

第10章 市場の将来展望

目次
Product Code: 61912

The market for prefilled syringes is projected to grow, owing to factors, such as increasing adoption of self-care devices, benefits associated with prefilled syringes, and high demand for improved safety in injectables.

The prefilled syringes make injections easy, accurate, and safe for, both, patients and doctors. Pre-filled syringes have emerged as one of the fastest-growing choices for unit dose medication, as the pharmaceutical industry seeks new and more convenient drug delivery methods.

In addition, pharmaceutical companies can get benefit by saving the cost of vials. The prefilled syringes work well with safety devices and auto-injection systems. Pharmaceutical companies are able to minimize drug waste and increase product life span, while patients are able to self-administer injectable drugs at their home instead of the hospital. Pre-filled syringes have also been utilized across a wide range of therapeutic sectors, such as vaccines, blood stimulants, and therapeutic proteins.

Eliminating dosing errors and ease of use are two of the greatest advantages of pre-filled syringes. Consequently, the differential advantages provided by prefilled syringes over traditional syringes are leading to the increased adoption and contributing to the global market growth.

Key Market Trends

Glass Prefilled Syringes are Projected to Experience Highest Growth Over the Forecast Period

The pharmaceutical industry uses glass syringes manufactured from Type 1 borosilicate glass, which consists primarily of silicon dioxide, along with oxides of boron, aluminum, sodium, and potassium. Metal ions, specifically sodium dioxide, are included in the mixture to alter the physical properties of the glass.

Glass syringes are manufactured from tubing glass. The glass tubing is created by heating the glass mixture to approximately 1500°C and continuously pulling the molten glass along a hollow spindle. Processing conditions, such as speed and airflow, are tightly controlled to prevent failures, such as airlines in the glass, from occurring. While glasses are generally unreactive, they are not necessarily inert. Alkali metals can leach out of glass, resulting in pH shifts in the solution. Some drug molecules are also labile for adsorption to the charged surface of the glass, resulting in decreased potency of the drug solution.

There have been reported instances when tungsten residues in the glass syringe Luer cone left behind during manufacturing have led to aggregation and particle formation in protein solutions. Apart from the above-mentioned challenges of drug interaction, glass prefilled syringes are also prone to breakage.

The market for glass prefilled syringes will grow regardless, albeit very sluggishly in the forecast period, primarily due to increased adoption of prefilled syringes in the developing regions, where glass syringes provide reusability and lower cost.

North America Dominates the Market

On January 22, 2013, the US FDA published the long-anticipated Final Rule: "Current Good Manufacturing Practice Requirements for Combination Products", with the purpose of clarifying regulatory requirements for quality systems used to design, develop, and manufacture combination products, and to help ensure consistent and appropriate application and enforcement of these requirements.

Prefilled drug delivery systems, including prefilled syringes, are combination products subject to the Final Rule. From a manufactures perspective, the Final Rule, as provided by the US FDA, tightens the regulations for syringe manufacturers and has made the manufacturing operation more stringent than before. This has acted as a deterrent to global players based in the United States and prevents them from expanding their regional operations, in other regions.

Overall, there is a large concentration of vendors supplying both end products and original components in the prefilled syringe market. The use of prefilled syringes in the United States is consequently ensured by the presence of appropriate vendors. Lifestyle associated illnesses and growing demand for easy-to-administer injectables in patients of chronic disease are helping the US prefilled syringe market flourish.

Competitive Landscape

The market for prefilled syringes is moderately competitive and there is high price competition in the market. The market is comprised of, both, global and local players. Most of the developing countries are having local players that provide prefilled syringes at a lower price. However, the market is majorly dominated by global companies. Few companies are expected to penetrate the market in the near future and they are expected to account for a substantial share of the prefilled syringes market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Adoption of Self-care Devices
    • 4.2.2 Benefits Associated with Prefilled Syringes
  • 4.3 Market Restraints
    • 4.3.1 Product Recalls
    • 4.3.2 Availability of Alternate Drug Delivery Methods
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Material
    • 5.1.1 Glass Prefilled Syringe
    • 5.1.2 Plastic Prefilled Syringe
  • 5.2 By Application
    • 5.2.1 Diabetes
    • 5.2.2 Anaphylaxis
    • 5.2.3 Rheumatoid Arthritis
    • 5.2.4 Oncology
    • 5.2.5 Other Applications
  • 5.3 By Type
    • 5.3.1 With Needle​
    • 5.3.2 Without Needle​
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 B. Braun Melsungen AG​
    • 6.1.3 Johnson & Johnson​
    • 6.1.4 Baxter International Inc.
    • 6.1.5 Terumo Corporation​
    • 6.1.6 Pfizer Inc.​
    • 6.1.7 Cardinal Health Inc.​
    • 6.1.8 Teva Pharmaceuticals Industries Ltd​
    • 6.1.9 Fresenius SE & Co. KGaA​
    • 6.1.10 Mylan NV ​
    • 6.1.11 Sanofi SA​

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.